Brittany Sauerborn, MD
Psychiatry · Beaufort, SCNPI 1538434923
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,875 of the $27,996 with a category attached, or 67.4%. AbbVie accounts for 71.9% of it on its own, with 11 other manufacturers making up the rest. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $147.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$6K
- Teva Pharmaceuticals USA, Inc.$844
- Otsuka America Pharmaceutical, Inc.$487
- Alkermes, Inc.$362
- E.r. Squibb & Sons, L.L.C.$277
- plus $381 from 6 others
What the payments were for
- Consulting fees$4,50016%
- Speaking & faculty fees$18,87567%
- Travel & lodging$1,4325%
- Food & beverage$3,07711%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $20,120 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 20 | $5,525 |
| Teva Pharmaceuticals USA, Inc. | 47 | $844 |
| Otsuka America Pharmaceutical, Inc. | 24 | $487 |
| Alkermes, Inc. | 19 | $362 |
| E.r. Squibb & Sons, L.L.C. | 14 | $277 |
| Neurocrine Biosciences, Inc. | 7 | $137 |
| Indivior Inc. | 4 | $99 |
| Johnson & Johnson | 4 | $72 |
| Lundbeck LLC | 2 | $31 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,996 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 42 | $409,673 |
| Invega SustennaPaliperidone Palmitate | 72 | $234,372 |
| Austedo XrDeutetrabenazine | 25 | $231,583 |
| IngrezzaValbenazine Tosylate | 17 | $141,895 |
| Abilify MaintenaAripiprazole | 46 | $124,204 |
| Abilify AsimtufiiAripiprazole | 21 | $121,552 |
| CaplytaLumateperone Tosylate | 53 | $92,877 |
| VraylarCariprazine Hcl | 36 | $55,136 |
| Risperdal ConstaRisperidone Microspheres | 16 | $39,106 |
| LybalviOlanzapine/Samidorphan Malate | 20 | $35,030 |
| Clozapine | 406 | $26,267 |
| RexultiBrexpiprazole | 16 | $22,544 |
| Risperidone ErRisperidone Microspheres | 19 | $14,371 |
| Lurasidone Hcl | 38 | $10,359 |
| Haloperidol Decanoate | 116 | $6,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $844 | $641,25567 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $72 | $273,47988 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Abilify Asimtufii, Rexulti | $487 | $268,30083 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $137 | $141,89517 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $5,525 | $92,87753 claims |
| AbbVieVraylar | $20,120 | $55,13636 claims |
| Alkermes, Inc.Lybalvi | $362 | $35,03020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Beaufort
- Brittany AlbrightMount Pleasant$691K
- Veronica RidpathFlorence$364K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Jeffrey StephensGreenville$195K
- Robert RichardsGreenville$142K
- Nikunjkumar ModiFlorence$133K
- Jacobo MintzerCharleston$132K
- Murray HonickMyrtle Beach$125K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.